Country/Region: Malaysia
PE Guidelines

Pharmacoeconomic Guideline For Malaysia (March 2012)
Pdf in English

PE Guidelines Source:

Ministry of Health of Malaysia

Additional Information:
Last Webpage Update: Thursday, April 28, 2016

PE Guidelines Key Features:

Key Features:  
Title and year of the document
Pharmacoeconomic Guideline For Malaysia 2012 
Affiliation of authors
PSD, MOH, MaHTAS, MySPOR, MPS,MUSC,UM,UKM,UKMMC, USM, UNU-IIGH, UiTM 
Purpose of the document
A methodological guide to conduct pharmacoeconomic analysis in Malaysia.  
Standard reporting format included
Yes 
Disclosure
Yes 
Target audience of funding/ author's interests
Both public and private payers, healthcare industries, clinicians, and research communities, accordingly. 
Perspective
Provider or funder. Patient and societal perspective are encouraged 
Indication
Indication(s) must be approved by DCA/reference country 
Target population
Must be clearly stated. 
Subgroup analysis
Yes, can be included when appropriate 
Choice of comparator
To be compared against the most relevant alternatives for the proposed indication in the applied setting. Comparator(s) should not be a placebo but non-drug therapy can be used. The choice of comparator(s) should always be justified. 
Time horizon
Should be long enough to capture all changes in cost(s) and outcome(s) of the intervention. 
Assumptions required
Yes. Should be clearly stated. 
Preferred analytical technique
CEA and CUA. Technique chosen should be justified clearly. 
Costs to be included
All costs relevant to the chosen perspective (provider/funder). Societal cost is preferred in any analysis. 
Source of costs
Local cost data in the applied setting. The source of cost data must be identified. 
Modeling
Yes. Clearly detailed with maximum transparency. All assumptions should be explicitly stated. 
Systematic review of evidences
Yes. Meta-analysis is encouraged. 
Preference for effectiveness over efficacy
N/A 
Preferred outcome measure
Should justify the selection. 
Preferred method to derive utility
Should justify the selection. 
Equity issues stated
N/A 
Discounting costs
3% (Sensitivity Analysis, 0 and 5%) 
Discounting outcomes
3% (Sensitivity Analysis, 0 and 5%) 
Sensitivity analysis-parameters and range
All key uncertain parameters. Best and worst case scenario presented. 
Sensitivity analysis-methods
One-way, multivariate analysis as deemed appropriate. 
Presenting results
Aggregated and disaggregated form for cost(s) and outcome(s). 
Incremental analysis
Yes 
Total costs vs effectiveness (cost/effectiveness ratio)
Yes 
Portability of results (Generalizability)
N/A 
Financial impact analysis
Yes 
Mandatory or recommended or voluntary
Voluntary for 2 years upon launch of the pharmacoeconomic guideline and mandatory thereafter. 

Acknowledgement: The ISPOR Malaysia Chapter (MySPOR) contributed to the key feature form.

Country Selection Page | PE Guidelines Index Page